Report #2835008

Received Apr 9, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Female
Age: Age unknown
State: TX
Recovered: Unknown
Vaccinated: Nov 4, 2023
Onset: Mar 21, 2025
Days to onset: 503
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
HEP	HEP B (HEPLISAV-B)	DYNAVAX TECHNOLOGIES CORPORATION	1	—	—

Symptoms (1)

Inappropriate schedule of product administration

Symptom narrative

Received 1st Dose on 04NOV2023 and now She is Here for the Second Dose; Initial report received on 21-Mar-2025. A pharmacist reported that a 53-year-old female (race, ethnicity not reported) received HEPLISAV-B (hepatitis B vaccine) for hepatitis B immunization on 04-Nov-2023 and returned to receive the second dose on 21-Nov-2025. No medical history or concomitant medications were reported. On 04-Nov-2023, the patient received dose 1 of a hepatitis B vaccine [HEPLISAV-B (lot #, expiration date, NDC #, route, site not reported)]. On 21-Mar-2025, 503 days after having been vaccinated with HEPLISAV-B, the patient presented to the pharmacy to receive the second dose. No additional information was reported. Company Comment: The company assessed the event as non-serious.; Sender's Comments: The company assessed the event as non-serious.